FDA Inspection
Avista Pharma Solutions, Inc.Avista Pharma Solutions, Inc. – FDA Inspection, Aug 14, 2026
Record Details
This FDA Inspection record concerns Avista Pharma Solutions, Inc., with an inspection on August 14, 2026, issued by the New England District Office, covering biologics.
- Inspection Date
- August 14, 2026
- Product Type
- Biologics
View Company Profile
ID · 5ddb9995-7883-41bf-b5d3-71b14a2b65d2
Inspection Facts
- Inspection number
- 1332618
- FDA center
- Biologics
- Project area
- Human Cellular, Tissue, and Gene Therapies
- Outcome
- Form 483 issued
FDA Citations
2- 21 CFR 211.194(a)Complete test data included in records
- 21 CFR 211.22(a)Approve or reject components, products
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Avista Pharma Solutions, Inc.
6| Date | Classification | Office | Project area |
|---|---|---|---|
| July 25, 2025 | VAI | New England District Office | Drug Quality Assurance |
| December 18, 2019 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| September 5, 2018 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| June 15, 2016 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| September 27, 2013 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Avista Pharma Solutions, Inc.
- FDA Inspection 1278383 - 2025-07-25
- FDA Inspection 1113974 - 2019-12-18
- FDA Inspection 1067530 - 2018-09-05
- FDA Inspection 988732 - 2016-06-15
- FDA Inspection 850250 - 2013-09-27
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.